COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Claire Holley

Claire Holley, PhD
Post-doctoral Fellow, Immunology

Dr. Holley is a Post-Doctoral Fellow in the immunology division at the Nanotechnology Characterization Laboratory (NCL). Her research, in collaboration with the FDA, focuses on quantifying the in vitro innate immune responses triggered by a variety of biotherapeutics and potential impurities produced during their manufacture. This project aims to standardize the screening protocols used for determining the immunogenicity of future biotherapeutics.

Prior to joining the NCL, Dr. Holley first received her B.A. in biochemistry and molecular, cellular, developmental biology from the University of Colorado-Boulder. She then earned an M.S. in biomedical science, with a focus in pathology/immunology, at the University of Texas Health Science Center-Houston. Her Master’s work focused on the immune cell response and antibody formation during the progression and treatment of Hemophilia A. Dr. Holley then proceeded to earn a Ph.D. in Biomedical Engineering from the University of Houston, where she developed targeted, controlled-release polymeric nanoformulations for the treatment of aggressive glioma, breast, and prostate cancers.